Achaogen - Top 15 Biotech VC Deals of 2010

Company: Achaogen
Based: South San Francisco
Amount: $56.31M

Investors: Frazier Healthcare Ventures, Alta Partners, 5 AM Ventures, ARCH Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust

Scoop: Last spring, 2009 Fierce 15 company Achaogen announced that it had raised $56 million in a Series C round of financing. New investors Frazier Healthcare Ventures and Alta Partners joined a syndicate of previous investors in the round.

"Our mission is to discover and develop life-saving antibiotics," CEO Kevin Judice (photo) said at the time. "This financing together with non-dilutive capital that we have secured through partnerships with various government agencies will enable us to advance multiple clinical programs, including conducting a Phase II study in complicated urinary tract infections of ACHN-490, our lead candidate for multi-drug resistant bacterial infections."

Achaogen - Top 15 Biotech VC Deals of 2010

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.